177
Views
14
CrossRef citations to date
0
Altmetric
Pharmaceutical Analysis

Chemometric Optimization of a RP‐HPLC Method for the Simultaneous Analysis of Abacavir, Lamivudine, and Zidovudine in Tablets

, , &
Pages 2649-2667 | Received 11 Jun 2004, Accepted 07 Jul 2004, Published online: 02 Feb 2007
 

Abstract

A method has been developed and validated for the separation of abacavir, lamivudine, and zidovudine by high‐performance liquid chromatography (HPLC) on a C18 column with uv detection at 270 nm. The optimal conditions for separation were determined with the aid of a “critical resolution map” technique using the program DryLab®. The effect of simultaneously varying the pH and proportion of methanol in the mobile phase was studied to optimize the separation. A response surface diagram was used to study the interaction between factors determining the separation. The mobile phase composition that provides an optimal resolution of components in an acceptable elution time is water:methanol (60:40 v/v) + 0.2% TEA and pH = 3.20 (pH adjusted with H3PO4). A method is applied for the analysis of Trizivir® tablets (Glaxo Wellcome, UK). The powdered tablets were extracted with methanol:water (50:50 v/v) mixture and after addition of stavudine as an internal standard subjected to HPLC analysis and assayed by comparison of analyte to internal standard peak areas to concentration ratios.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.